Shaperon, a Korean biotech company, said it will work with Sadick Research Group, an international skincare practice and research center based in New York, to develop dermatology-related products. 

The collaboration originated from discussions initiated last year when Seong Seung-yong, CEO of Shaperon, visited Sadick Research Group's headquarters in Manhattan, New York.

Shaperon expressed optimism for support in facilitating their entry into the U.S. market with Nugel, its treatment for atopic dermatitis  — often referred to as eczema — a chronic disease that causes inflammation, redness, and irritation of the skin. 

Shaperon emphasized the importance of leveraging Sadick Research Group’s network of dermatology companies to expedite tangible outcomes, aiming for “early market entry with market-friendly products, informed by insights from leading dermatologists in the U.S.”

In his endorsement of the collaboration, Dr. Neil Sadick underscored the mutual benefits for Sadick Research Group and Shaperon.

The primary focus is on “advancing the successful clinical progression and technology transfer of Nugel, currently in phase 2 trials in the U.S., along with strategic planning and marketing initiatives for various dermatology-related products," as integral parts of the collaboration with Shaperon, he said. 

Dr. Sadick, the President of Sadick Research Group and a renowned dermatologist, currently serves as the Chief of Dermatology at Weill Cornell Medical College in New York City.